He bought puts on JAZZ and nailed it. Plans to buy puts on ARNA as well. Lastly, he will buy calls on BIOD. His track record is impressive (called VVUS decline as well)...I think it's wise to keep an eye on his opinions.
He calls BIOD a $30/sh stock. Want to bet against him?
BIOD won't be staying in the low $4's for long!
Bay: Oh your so wrong on the weight loss front! A reasonable percentage in ARNA big trials lost over 30 lbs! Not all but some-and a larger percentage lost over 15 lbs! Go look at the NEJM data OR "Learn the hard way"!
Kiwi: "Funding" Now I understand what you are talking about!
You may be surprised on that funding for this weight loss drug if ya look at the data generated for things Hb1Ac and other metabolic parameters that occur off the weight loss!! The DM data (before end of the year) will open a whole new line into managment of diabetes and with it will be insurance coverage easy.
This will not only get approved, it will later get approval for a line extention in diabetes and thats 10's of million more patients!
I see you are an ARNA fan and GLTU.
I agree with you generally, my point about funding relates to Federal funding of the drug itself.
My understanding is that under a weight loss category the drug gets none.
However ARNA itself is ready for commercialization of the drug thru it's partners and funding.
Going with both a good idea kutz